Barry Sigal
Pulmonary Disease · Charleston, SCNPI 1316929102
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,511 of the $2,065 with a category attached, or 73.2%. 27 manufacturers reported payments, led by Shionogi Inc at 34.7% of the total. Reporting peaked in 2020 at $1,066 and has fallen 98.4% since, to $17 in 2023. That places this record below the midpoint for pulmonary disease clinicians in SC, where the typical reported total is $2,769.
Across 74 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$716
- La Jolla Pharmaceutical Company$246
- GSK$220
- Boehringer Ingelheim$144
- AstraZeneca$85
- CSL Behring$66
- plus $588 from 21 others
Across 479 payments — averaging $2911.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$459K
- Boehringer Ingelheim$204K
- AstraZeneca$195K
- Insmed, Inc.$156K
- GSK$130K
- Shionogi Inc$122K
- plus $130K from 11 others
What the payments were for
- Travel & lodging$48824%
- Food & beverage$1,51173%
- Education$663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 7 | $716 |
| La Jolla Pharmaceutical Company | 2 | $246 |
| GSK | 16 | $220 |
| Boehringer Ingelheim | 4 | $144 |
| AstraZeneca(2 entities) | 7 | $85 |
| CSL Behring | 4 | $66 |
| Grifols USA, LLC | 2 | $62 |
| Gilead | 4 | $53 |
| Novartis | 3 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Philips North America LLC | 1 | $40 |
| Pfizer | 3 | $37 |
| Bio Products Laboratory USA, Inc. | 1 | $35 |
| Insmed, Inc. | 2 | $28 |
| Genentech USA, Inc. | 2 | $28 |
| Covis Pharma GmbH | 2 | $26 |
| Mylan Specialty L.p. | 2 | $26 |
| Sanofi | 1 | $25 |
| United Therapeutics Corporation | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Hospira, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Phadia US Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIAPREZA$246
How this compares
$2,065 in reported general payments places this provider in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,827 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $220 | $19,57833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Charleston
- Patrick FlumeCharleston$418K
- Gerard SilvestriCharleston$254K
- Denise Gabrielle SeseCharleston$51K
- Timothy WhelanCharleston$41K
- Marc JudsonCharleston$28K
- John HugginsCharleston$18K
- John CoxCharleston$16K
- Adam FoxCharleston$13K
- Michael SpandorferCharleston$12K
- Rachana KrishnaCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.